TY - JOUR
T1 - Review of Novel Third-Generation Tetracyclines
T2 - Eravacycline, Omadacycline, and Sarecycline
AU - Kim, Do Young
AU - McElvania, Erin
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/4/15
Y1 - 2023/4/15
N2 - Tetracycline class antibiotics have activity against a wide range of Gram-positive, Gram-negative, and atypical bacterial pathogens, and they have been used for treatment of various infections, including respiratory infections, skin and soft tissue infections, and sexually transmitted infections. Increases in morbidity and mortality associated with infections by multidrug-resistant organisms have highlighted the need for new antibiotics. In 2018, three novel tetracyclines were approved by the FDA: eravacycline, omadacycline, and sarecycline. This review discusses the pharmacological properties and microbiological and clinical aspects of these new tetracyclines.
AB - Tetracycline class antibiotics have activity against a wide range of Gram-positive, Gram-negative, and atypical bacterial pathogens, and they have been used for treatment of various infections, including respiratory infections, skin and soft tissue infections, and sexually transmitted infections. Increases in morbidity and mortality associated with infections by multidrug-resistant organisms have highlighted the need for new antibiotics. In 2018, three novel tetracyclines were approved by the FDA: eravacycline, omadacycline, and sarecycline. This review discusses the pharmacological properties and microbiological and clinical aspects of these new tetracyclines.
UR - http://www.scopus.com/inward/record.url?scp=85154057990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85154057990&partnerID=8YFLogxK
U2 - 10.1016/j.clinmicnews.2023.04.001
DO - 10.1016/j.clinmicnews.2023.04.001
M3 - Article
AN - SCOPUS:85154057990
SN - 0196-4399
VL - 45
SP - 61
EP - 67
JO - Clinical Microbiology Newsletter
JF - Clinical Microbiology Newsletter
IS - 8
ER -